^
Association details:
| Biomarker: | MCL1 overexpression |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | ME-344 (mTOR inhibitor, Mitochondrial OXHPHOS inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
3785 / 16 - ME-344, a novel isoflavone mitochondrial inhibitor, in combination with venetoclax constitutes a new metabolism-targeted approach to overcome resistance to Bcl-2 inhibition and standard of care treatment in AML
Published date:
03/09/2022
Excerpt:
...we investigated the preclinical activity of ME-344, a novel isoflavone OXPHOS inhibitor, on AML cell lines and relapsed/refractory (R/R) patient samples in vitro and examined the efficacy of ME-344 in combination with VEN in Ara-C sensitive and resistant AML cell lines and patient-derived xenografts (PDX) both in vitro and in vivo....The dual inhibition of OXPHOS/Bcl-2 reduced Mcl-1 levels and showed efficacy in Mcl-1 overexpressing and Ara-C resistant AML models.
